Evaxion Biotech A/S ADR EVAX 深 沪
等待开盘 11-04 09:30:00 美东时间
5.77
+0.020
+0.35%
华盛通- 最 高5.98
- 今 开5.89
- 成交量 15.75万股
- 最 低 5.5101
- 昨 收 5.75
- 总市值 3644.68万
- 52周最高 13.15
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.20
- 委 比 60.44%
- 总股本 631.66万
- 历史最高 1252.00
- 量 比 0.61
- 振 幅 8.17%
- 历史最低 4.025
- 每 手 1
- 风险率 2.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evaxion Unveils AI-Designed Cancer Vaccine Candidate EVX-04
Evaxion Biotech ( ($EVAX) ) has shared an update. On November 3, 2025, Evaxion ...
11-03 22:48
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Edward Jones Initiates Coverage On Evaxion with Buy Rating, Announces Price Target of $10
Edward Jones analyst Soumit Roy initiates coverage on Evaxion (NASDAQ:EVAX) with a Buy rating and announces Price Target of $10.
10-30 20:55
Evaxion A/S Secures $7.2 Million to Extend Cash Runway
An announcement from Evaxion Biotech ( ($EVAX) ) is now available. On October 3...
10-30 20:53
Evaxion names Helen Tayton-Martin as new CEO
Evaxion A/S (EVAX) has appointed Helen Tayton-Martin as the new chief executive officer, it said on Monday. She will take up her new position on November 24 and simultaneously step down from Evaxion’s...
10-27 20:13
Evaxion A/S Appoints Helen Tayton-Martin CEO, Effective Nov. 24
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has appointed Dr Helen Tayton-Martin as new Chief Executive Officer (CEO). She
10-27 20:05
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
Evaxion appoints Helen Tayton-Martin as CEO, bringing extensive biotech experience, strategic partnerships, and leadership. She replaces interim CEO Birgitte Rønø, who remains Chief Scientific Officer. Jens Bitsch-Norhave joins the Board as an advisor and observer.
10-27 12:00
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Lake Street Maintains Buy on Evaxion, Raises Price Target to $11
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price target from $6 to $11.
10-20 21:16
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvard scientists recently created...
10-17 21:50
